|
|
 Previous Article | Table of Contents | Next Article 
Prognostic Significance of Bax Protein Expression in Diffuse Aggressive Non-Hodgkin's Lymphoma
Randy D. Gascoyne,
Maryla Krajewska,
Stanislaw Krajewski,
Joseph M. Connors, and
John C. Reed
From The Burnham Institute (S.K., M.K., and J.C.R.), Cancer Research Center, La Jolla, CA and The Departments of Pathology (R.D.G.) and Medical Oncology (J.M.C.), British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada.
Bax is a proapoptotic member of the Bcl-2 protein family. The incidence and prognostic significance of Bax protein expression in diffuse non-Hodgkin's lymphomas with a large cell component (DLCL) was determined by an immunohistochemical method by using paraffin-embedded tumors from a cohort of patients treated uniformly with combination chemotherapy (n = 139). All patients were between 16 and 70 years of age and had advanced stage disease of diffuse large cell type (diffuse mixed, diffuse large cell, immunoblastic, or anaplastic large cell). Paraffin sections from diagnostic biopsies were successfully immunostained for Bax in 113 cases. Of these, 7 (6%) tumors were scored as Bax immunonegative (<1% Bax-stained tumor cells), 42 (37%) as low (1% to 10%), 9 (8%) as low-intermediate (11% to 30%), 25 (22%) as high-intermediate (31% to 70%), and 30 specimens (27%) as high for Bax expression (<70%). Of the 7 Bax-immunonegative lymphomas, all also scored low ( 10% immunostained tumor cells) for Bcl-2 expression, whereas 78 of the 106 (74%) Bax-immunopositive tumors had low Bcl-2 expression. By itself, Bax expression was not of prognostic significance in univariate analysis, although there was a clear trend for patients with Bax-immunonegative lymphomas (n = 7) to relapse sooner and to die faster than patients whose tumors contained Bax-immunopositive malignant cells (n = 106; 8-year overall survival 29% versus 55%; P = .06). When combined with Bcl-2 immunostaining data, Bax provided additional prognostic information. Among patients with Bcl-2 low-expressing DLCLs, for example, Bax immunonegativity was associated with lower 8-year relapse-free survival (RFS; 29% v 61%; P < .01) and lower 8-year overall survival (OS; 29% v 63%; P < .05), suggesting that absence of Bax protein connotes a more aggressive phenotype when Bcl-2 protein is also not expressed at high levels. In contrast, low Bax expression was associated with improved 8-year disease-free survival (52% v 16%; P < .02), RFS (47% v 11%; P < .02), and OS (64% v 11%; P < .01) in patients whose tumors expressed Bcl-2 at high levels, suggesting that the combination of high levels of Bax and Bcl-2 expression is more deleterious than high levels of Bcl-2 expression alone. Bax expression failed to provide additional prognostic information beyond Bcl-2 expression in multivariate analysis that included the clinical International Prognostic Index factors (age, stage, lactate dehydrogenase, performance status, and number of extranodal sites) and immunophenotype. Taken together, the results suggest that Bax expression is not a major prognostic marker in DLCL. However, the interactions of the Bcl-2 and Bax expression data with respect to clinical outcome may shed new insights into the biological significance of Bcl-2/Bax protein heterodimerization.
Blood, Vol. 90 No. 8 (July 15), 1997:
pp. 3173-3178
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. H. Olejniczak, F. J. Hernandez-Ilizaliturri, J. L. Clements, and M. S. Czuczman
Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression
Clin. Cancer Res.,
March 1, 2008;
14(5):
1550 - 1560.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev,
January 1, 2007;
87(1):
99 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saxena, M. Bosch, T. Qureshi, K. Nokhrina, and O. Moshynska
Effect of Bax G125A Single Nucleotide Polymorphism (SNP) on Bax Gene Expression in Diffuse Large Cell Lymphoma.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
4379 - 4379.
[Abstract]
|
|
|
|
|
|
|
D Santini, G Tonini, F M Vecchio, D Borzomati, B Vincenzi, S Valeri, A Antinori, F Castri, R Coppola, P Magistrelli, et al.
Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma
J. Clin. Pathol.,
February 1, 2005;
58(2):
159 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Barrans, I. Carter, R. G. Owen, F. E. Davies, R. D. Patmore, A. P. Haynes, G. J. Morgan, and A. S. Jack
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
Blood,
February 15, 2002;
99(4):
1136 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Z. Rassidakis, L. J. Medeiros, T. J. McDonnell, S. Viviani, V. Bonfante, G. Nadali, T. P. Vassilakopoulos, R. Giardini, M. Chilosi, C. Kittas, et al.
BAX Expression in Hodgkin and Reed-Sternberg Cells of Hodgkin's Disease: Correlation with Clinical Outcome
Clin. Cancer Res.,
February 1, 2002;
8(2):
488 - 493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Z. Rassidakis, A. H. Sarris, M. Herling, R. J. Ford, F. Cabanillas, T. J. McDonnell, and L. J. Medeiros
Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage
Am. J. Pathol.,
August 1, 2001;
159(2):
527 - 535.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
I. Sturm, H. Petrowsky, R. Volz, M. Lorenz, S. Radetzki, T. Hillebrand, G. Wolff, S. Hauptmann, B. Dorken, and P. T. Daniel
Analysis of p53/BAX/p16ink4a/CDKN2 in Esophageal Squamous Cell Carcinoma: High BAX and p16ink4a/CDKN2 Identifies Patients With Good Prognosis
J. Clin. Oncol.,
April 15, 2001;
19(8):
2272 - 2281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Renner, J. Weisz, S. Krajewski, M. Krajewska, J. C. Reed, and A. Lichtenstein
Expression of BAX in Plasma Cell Dyscrasias
Clin. Cancer Res.,
June 1, 2000;
6(6):
2371 - 2380.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. I. Gordon, M. Young, E. Weller, T. M. Habermann, J. N. Winter, J. Glick, C. Ghosh, P. Flynn, and P. A. Cassileth
A Phase II Trial of 200% ProMACE-CytaBOM in Patients With Previously Untreated Aggressive Lymphomas: Analysis of Response, Toxicity, and Dose Intensity
Blood,
November 15, 1999;
94(10):
3307 - 3314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bairey, Y. Zimra, M. Shaklai, E. Okon, and E. Rabizadeh
Bcl-2, Bcl-X, Bax, and Bak Expression in Short- and Long-Lived Patients with Diffuse Large B-Cell Lymphomas
Clin. Cancer Res.,
October 1, 1999;
5(10):
2860 - 2866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sturm, C.-H. Kohne, G. Wolff, H. Petrowsky, T. Hillebrand, S. Hauptmann, M. Lorenz, B. Dorken, and P. T. Daniel
Analysis of the p53/BAX Pathway in Colorectal Cancer: Low BAX Is a Negative Prognostic Factor in Patients With Resected Liver Metastases
J. Clin. Oncol.,
May 1, 1999;
17(5):
1364 - 1364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Moller, A.-M. Gerdes, K. Skjodt, L. S. Mortensen, and N. T. Pedersen
Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
May 1, 1999;
5(5):
1085 - 1091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nicolaides, S. Dimou, and N. Pavlidis
Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas
Oncologist,
June 1, 1998;
3(3):
189 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. C. Thornborrow and J. J. Manfredi
The Tumor Suppressor Protein p53 Requires a Cofactor to Activate Transcriptionally the Human BAX Promoter
J. Biol. Chem.,
May 4, 2001;
276(19):
15598 - 15608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
